Table 3.

TNB-486 mediates lysis of tumor cells derived from leukemia or lymphoma patients. Lysis of CD19+ cells from ex vivo patient derived PBMCs or dissociated tumor cells (DTCs) was evaluated by flow cytometry. Average % lysis of tumor cells is shown

Ex Vivo Sample Type	Effector:Target Ratio	CD19 Antigen Density (x103)d	Average % lysis of tumor cellse
Lymphoma, NOS	1.707b	7.6	2.3a
NHL, Extranodal Marginal Zone B cell (MALT: Mucosa-Associated Lymphoid Tissue)	0.01b	NT	-1.4
NHL, Extranodal Marginal Zone B cell (MALT: Mucosa-Associated Lymphoid Tissue) PBMC	12.54b	20.7	55.7
NHL, Diffuse Large B cell Lymphoma	25.95b	7.6	25.4a
CLL PBMC	10c	70.3	18.2
CLL PBMC	10c	20.4	14.9
NHL	2 b	-	28.2
CLL PBMCf	10c	97.9	44.4
	0.064b		17.5

^aAssay incubation time was 24 hours

^bEffector to target cell ratio was left unaltered

^cEffector to target cell ratio was adjusted to indicated value

^dAntibody used for antigen density estimate; Biolegend Cat#302208 Clone#HIB19

^eNormalized to control samples without antibody

^fSame sample was tested with and without modifying E:T ratio as indicated in column 2.